Ipamorelin vs Sermorelin: two routes to the same axis
Ipamorelin and Sermorelin are often filed under the same label — 'GH secretagogues' — because both aim to make the pituitary release more of the body's own growth hormone (GH) rather than supplying GH from outside. But they reach that result through different molecular doors: Ipamorelin mimics ghrelin and activates the GHS-R1a receptor, while Sermorelin reproduces the hypothalamic hormone GHRH and activates the GHRH receptor. Understanding that distinction is exactly what explains why they are studied separately and why they are sometimes described together in the literature. This guide is purely educational: neither is an approved medicine for human use in most jurisdictions, and no dosing guidance is included here.
| Ipamorelin | Sermorelin | |
|---|---|---|
| Class | GHRP / ghrelin mimetic (GHS-type secretagogue) | GHRH analogue (GHRH 1-29 fragment) |
| Target receptor | Ghrelin receptor GHS-R1a on pituitary somatotrophs | GHRH receptor on pituitary somatotrophs |
| Mechanism on the GH axis | Activates the ghrelin pathway to amplify the GH pulse; may blunt somatostatin tone | Reproduces the physiologic GHRH signal that tells the pituitary to release pulsatile GH |
| Selectivity | Described as more 'selective': preclinically it did not meaningfully raise ACTH, cortisol or prolactin | Selective by design: it is the native GHRH(1-29) sequence itself, preserving feedback (somatostatin, IGF-1) |
| Evidence base | Mostly preclinical and early-phase; a human trial in postoperative ileus did not meet its endpoint | Older clinical base; FDA-approved (Geref) for diagnosis and pediatric GH deficiency, now discontinued |
| Regulatory status | Not approved (FDA/EMA/MHRA); marketed as RUO / research chemical | Geref discontinued (2008-2009); survives in the US via 503A compounding with a prescription; no authorization in EU/UK |
| Anti-doping status (WADA) | Prohibited: GH secretagogues appear in class S2 of the Prohibited List (in and out of competition) | Prohibited: GHRH-receptor agonists appear in class S2 of the Prohibited List (in and out of competition) |
The same goal, two different receptors
Growth hormone is released from the pituitary under two opposing signals: GHRH from the hypothalamus stimulates it, and somatostatin restrains it. On top of that, ghrelin — a mainly digestive hormone — also pushes GH release through its own receptor, GHS-R1a. Ipamorelin and Sermorelin each work one of these levers. Ipamorelin is a synthetic pentapeptide that mimics ghrelin and activates GHS-R1a; the literature calls it a 'secretagogue' because it prompts the gland to secrete its own GH. Sermorelin, by contrast, is literally a fragment of human GHRH (the first 29 amino acids, which retain the activity of the full hormone) and activates the GHRH receptor. The final destination is the same — more pulsatile GH, and secondarily more IGF-1 — but the point of entry differs. That is the core idea of this comparison: they do not compete for the same receptor; they push the same axis from two different points.
Selectivity and why people talk about a 'clean' signal
When the first GH-releasing peptides appeared (GHRP-6, GHRP-2), they were found to move not only GH but also other stress-axis hormones such as ACTH, cortisol and prolactin. The research interest in Ipamorelin was precisely that, at doses that stimulated GH, it did not meaningfully raise those other hormones — hence its description as the first 'selective' secretagogue of its family. Sermorelin approaches selectivity from a different angle: being the natural GHRH sequence itself, it works within the physiologic circuit and leaves the body's brakes intact. Because it acts upstream of the pituitary and does not supply GH directly, its effect depends on there still being somatotrophs able to respond, and it respects the negative feedback of somatostatin and IGF-1 in a way that direct administration of exogenous GH does not. It is worth not confusing 'selective' or 'physiologic' with 'harmless': both are substances not approved for general use, and their long-term safety in healthy populations is not established in controlled trials.
Why the literature sometimes pairs GHRH + GHRP
A recurring observation in GH-axis physiology is that a GHRH-type signal (like Sermorelin) and a GHRP/ghrelin-type signal (like Ipamorelin) act on different receptors and, in doing so, can have complementary effects: the former provides the physiologic 'background' stimulus and the latter amplifies the pulse and reduces the somatostatin brake. That is why research texts and experimental protocols often present the logic of pairing a GHRH analogue with a GHRP. It is important to frame this as a mechanistic concept described in the literature, not as a recommendation: this guide proposes combining nothing, gives no dosing and suggests no human use. That two pathways are theoretically complementary does not mean combining them is safe, legal or clinically validated; in fact, controlled human evidence for each compound alone is already limited, and for combinations in healthy adults it is essentially nonexistent.
Evidence, regulatory status and anti-doping
The two molecules sit at very different points of maturity. Ipamorelin has a mostly preclinical, early-phase base; its foundational characterization (Raun et al., 1998) described its GH-releasing potency and selectivity, and the most-cited human trial (Beck et al., 2014) tested it for postoperative ileus — a different goal — without reaching statistical significance over placebo. Sermorelin has a longer clinical history: it was FDA-approved as Geref for diagnosis (1990) and for pediatric GH deficiency (1997), with a study in older men (Corpas et al., 1992) showing reversal of the decline in pulsatile GH and IGF-1; but the original product was discontinued for commercial reasons and today circulates mainly as compounded product (US, by prescription) or research material. As for status: neither is approved as a general-use drug in the EU or the UK, and both are commonly referenced as RUO. On the sporting side, both GH secretagogues and GHRH-receptor agonists appear in class S2 of the WADA Prohibited List, banned at all times (in and out of competition). In short: same axis, two routes, and in both cases substances not approved for human use that call for caution and independent third-party quality verification.
Frequently asked questions
- What is the main difference between Ipamorelin and Sermorelin?
- They act on the same axis — getting the pituitary to release more of its own growth hormone — but through different receptors. Ipamorelin mimics ghrelin and activates the GHS-R1a receptor (it is a GHRP/ghrelin-type secretagogue); Sermorelin reproduces the GHRH hormone and activates the GHRH receptor (it is a GHRH analogue). The intended result is similar; the molecular door is not.
- Why does research sometimes combine a GHRH signal and a GHRP?
- Because they act on different receptors and, according to the physiology described in the literature, their effects on the GH pulse can be complementary: the GHRH pathway provides the background stimulus and the GHRP/ghrelin pathway amplifies the pulse and blunts the somatostatin brake. It is a mechanistic concept, not a recommendation: this guide is educational, gives no dosing and suggests no human use, and controlled evidence for combinations in healthy adults is practically nonexistent.
- Are they approved or allowed in sport?
- Not for general use: neither Ipamorelin nor Sermorelin is approved as a human medicine in the EU or UK, and they are typically referenced as RUO (research use only). In sport, both GH secretagogues and GHRH-receptor agonists appear in class S2 of the WADA Prohibited List and are banned at all times, in and out of competition. Regulatory status varies by jurisdiction and can change.
✓ Last reviewed · 2026-07-24